中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
12期
27-28
,共2页
慢性收缩性心力衰竭%重组人纽兰格林%6 min步行试验
慢性收縮性心力衰竭%重組人紐蘭格林%6 min步行試驗
만성수축성심력쇠갈%중조인뉴란격림%6 min보행시험
Chronic systolic heart failure%Neregurelin%6 min walking test
目的 评价注射用重组人纽兰格林或安慰剂对慢性收缩性心力衰竭患者的临床疗效及安全性.方法 将入选的11例患者进行随机、双盲、在标准治疗基础上的安慰剂并行对照研究.试验组给予注射用重组人纽兰格林+基础治疗药物(ACEI/ARB、β-受体阻滞剂、利尿剂、地高辛),安慰剂组给予安慰剂+上述基础治疗药物,每天给药10 h,连续给药10 d,观察入组时、第11、30、90天6 min步行距离、QOL评分,并记录研究周期内的不良事件.结果 试验组在研究周期第11、30、90天6 min步行距离大于对照组(P<0.05),试验组QOL评分低于对照组(P<0.05),试验组不良反应发生率高于对照组.结论 短期内静脉应用重组人纽兰格林可以改善慢性收缩性心力衰竭患者的心功能,提高生活质量.
目的 評價註射用重組人紐蘭格林或安慰劑對慢性收縮性心力衰竭患者的臨床療效及安全性.方法 將入選的11例患者進行隨機、雙盲、在標準治療基礎上的安慰劑併行對照研究.試驗組給予註射用重組人紐蘭格林+基礎治療藥物(ACEI/ARB、β-受體阻滯劑、利尿劑、地高辛),安慰劑組給予安慰劑+上述基礎治療藥物,每天給藥10 h,連續給藥10 d,觀察入組時、第11、30、90天6 min步行距離、QOL評分,併記錄研究週期內的不良事件.結果 試驗組在研究週期第11、30、90天6 min步行距離大于對照組(P<0.05),試驗組QOL評分低于對照組(P<0.05),試驗組不良反應髮生率高于對照組.結論 短期內靜脈應用重組人紐蘭格林可以改善慢性收縮性心力衰竭患者的心功能,提高生活質量.
목적 평개주사용중조인뉴란격림혹안위제대만성수축성심력쇠갈환자적림상료효급안전성.방법 장입선적11례환자진행수궤、쌍맹、재표준치료기출상적안위제병행대조연구.시험조급여주사용중조인뉴란격림+기출치료약물(ACEI/ARB、β-수체조체제、이뇨제、지고신),안위제조급여안위제+상술기출치료약물,매천급약10 h,련속급약10 d,관찰입조시、제11、30、90천6 min보행거리、QOL평분,병기록연구주기내적불량사건.결과 시험조재연구주기제11、30、90천6 min보행거리대우대조조(P<0.05),시험조QOL평분저우대조조(P<0.05),시험조불량반응발생솔고우대조조.결론 단기내정맥응용중조인뉴란격림가이개선만성수축성심력쇠갈환자적심공능,제고생활질량.
Objective Testimating the effect of clinical therapy and safety with injection recombinant human Neuregulin-1 (rhNRG-1)and placebo for chronic systolic heart failure patients. Methods A total of 11 CHF patients were enrolled in a randomized manner, double-blind, and treated with a placebo-controlled study. The experimental group was given neregurelin+basis medication(ACEI/ARB,β-blocker,digoxin and diutics). The placebo group was given placebo+previous basis medication. Everyday dose 10 hours, sequence for 10 days. Observing the changes of 6 minites walk test distance and quality of life score for 0 day, 11th day,30th day,90th day. Recording adverse events in study periods. Results Comparing the 6 minutes walk test and quality of life score of the entrolled day with the 11th day,30th,90th day,distance of 6 minites test apparently increased,quality of life score decreases,and there was statistical distinction (P<0.05), the incidence of adverse reaction in the experimental group was increased. Conclusions Injection rhNRG-1 is utilized in the short term improved the cardiac function and heightened quality of life of CHF patients.
